Structure-based and AI-guided redesign of Sotrovimab for enhanced recognition of SARS-CoV-2 BA.2 and the E340G escape mutant

Introduction The rapid evolution of SARS-CoV-2 Omicron variants has substantially compromised the efficacy of several monoclonal antibody therapies, including Sotrovimab, through mutations that disrupt antibody–antigen recognition. Developing antibodies with improved recognition of emerging variants and resistance-associated mutations is therefore essential for maintaining therapeutic effectiveness. Methods Here, we employed an integrated computational framework combining structure-guided antibody engineering, artificial intelligence (AI)-assisted sequence design, molecular dynamics (MD) simulations, and binding free-energy analyses to redesign Sotrovimab against the Omicron BA.2 receptor-binding domain (RBD) and the clinically relevant E340G escape mutant. Residue-level energetic profiling was used to identify destabilizing interface residues, followed by mutational redesign and ProteinMPNN-guided sequence optimization. The resulting candidates were evaluated through 500 ns all-atom MD simulations, complemented by conformational analyses, MM/PBSA binding free-energy calculations, residue-level energy decomposition, and dynamic cross-correlation analyses. Results and Discussion The top-ranked redesigned Sotrovimab candidates retained the characteristic immunoglobulin fold while exhibiting improved structural stability, compactness, and reduced conformational fluctuations. Principal component analysis and free-energy landscape calculations further revealed more confined and energetically favorable conformational states, suggesting enhanced dynamic compatibility with the target RBD. MM/PBSA calculations indicated substantially more favorable binding free energies for both redesigned candidates against the BA.2 RBD and E340G mutant. Residue-level energy decomposition and dynamic cross-correlation analyses further demonstrated improved energetic complementarity and intermolecular communication across the antibody–antigen interface. These improvements were accompanied by enhanced hydrogen-bonding, hydrophobic, and van der Waals interactions, together with increased engagement of the conserved N343-linked glycan, potentially providing additional stabilization to the antibody -antigen complex. Among the redesigned candidates, Sotrovimab-design-2 consistently exhibited the most favorable structural and energetic characteristics. Conclusion Collectively, these findings demonstrate the potential of integrating AI-guided sequence optimization with structure-based antibody engineering to improve antibody recognition of SARS-CoV-2 variants and resistance-associated mutations. This framework provides a computational foundation for developing mutation-resilient therapeutic antibodies against evolving viral pathogens.

Authors

Institutions

Publication Details

Journal
Frontiers in Chemical Biology
Published
2026-11-13
DOI
https://doi.org/10.3389/fchbi.2026.1981996
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Structure-based and AI-guided redesign of Sotrovimab for enhanced recognition of SARS-CoV-2 BA.2 and the E340G escape mutant

Aditya Kumar Padhi, Amar Jeet Yadav, Ankit Kumar
3 links
Frontiers in Chemical Biology
SARS-CoV-2 and COVID-19 Research
article

Structure-based and AI-guided redesign of Sotrovimab for enhanced recognition of SARS-CoV-2 BA.2 and the E340G escape mutant

Aditya Kumar Padhi, Amar Jeet Yadav, Ankit Kumar
article en

Abstract

Introduction The rapid evolution of SARS-CoV-2 Omicron variants has substantially compromised the efficacy of several monoclonal antibody therapies, including Sotrovimab, through mutations that disrupt antibody–antigen recognition. Developing antibodies with improved recognition of emerging variants and resistance-associated mutations is therefore essential for maintaining therapeutic effectiveness. Methods Here, we employed an integrated computational framework combining structure-guided antibody engineering, artificial intelligence (AI)-assisted sequence design, molecular dynamics (MD) simulations, and binding free-energy analyses to redesign Sotrovimab against the Omicron BA.2 receptor-binding domain (RBD) and the clinically relevant E340G escape mutant. Residue-level energetic profiling was used to identify destabilizing interface residues, followed by mutational redesign and ProteinMPNN-guided sequence optimization. The resulting candidates were evaluated through 500 ns all-atom MD simulations, complemented by conformational analyses, MM/PBSA binding free-energy calculations, residue-level energy decomposition, and dynamic cross-correlation analyses. Results and Discussion The top-ranked redesigned Sotrovimab candidates retained the characteristic immunoglobulin fold while exhibiting improved structural stability, compactness, and reduced conformational fluctuations. Principal component analysis and free-energy landscape calculations further revealed more confined and energetically favorable conformational states, suggesting enhanced dynamic compatibility with the target RBD. MM/PBSA calculations indicated substantially more favorable binding free energies for both redesigned candidates against the BA.2 RBD and E340G mutant. Residue-level energy decomposition and dynamic cross-correlation analyses further demonstrated improved energetic complementarity and intermolecular communication across the antibody–antigen interface. These improvements were accompanied by enhanced hydrogen-bonding, hydrophobic, and van der Waals interactions, together with increased engagement of the conserved N343-linked glycan, potentially providing additional stabilization to the antibody -antigen complex. Among the redesigned candidates, Sotrovimab-design-2 consistently exhibited the most favorable structural and energetic characteristics. Conclusion Collectively, these findings demonstrate the potential of integrating AI-guided sequence optimization with structure-based antibody engineering to improve antibody recognition of SARS-CoV-2 variants and resistance-associated mutations. This framework provides a computational foundation for developing mutation-resilient therapeutic antibodies against evolving viral pathogens.

Frontiers in Chemical BiologyVol. 5
Indian Institute of Technology BHU (IN), Banaras Hindu University (IN)
Good health and well-being
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon